New hope for advanced solid tumors! FDA approves MOR210 / TJ210 for the treatment of IND for advanced solid tumors.

MorphoSys and I-Mab recently jointly announced that the U.S. Food and Drug Administration (FDA) has approved a new research drug application (IND) to allow research-based human anti-C5aR1 antibody MOR210 / TJ210 to treat recurring or refractic late-stage solid tumor clinical trials designed to evaluate the safety, toerability, pharmacodynamics and pharmacology of MOR210 / TJ210.
MOR210 / TJ210 is a monoclonal antibody against the differentiation factor C5a subject 1 (C5aR1).
C5a produced by tumor and substitut cells attracts immunosuppressive cells, such as M2 macrophages and neutrino granulocytes, through the expression of C5aR1 on their surface, thus creating a tumor micro-environment that is detrimental to T cells.
MOR210 / TJ210 blocks the interaction between C5a and C5aR1 by binding to C5aR1 and delays the migration of immunosuppressive cells.
preclinical studies have shown that MOR210 / TJ210, in combined with immuno-checkpoint inhibitors, can provide strong anti-tumor activity.
Joan Shen, chief executive of I-Mab, said: "MOR210 / TJ210 has shown encouraging results in preclinical studies.
We look forward to applying MOR210 / TJ210 to clinical studies, which will enable us to assurcen the safety and tolerance of MOR210 / TJ210 and its potential clinical benefits in cancer patients."
.